TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
EMPLOYEES
Novartis Sverige AB
Closing information (x1000 NOK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
2,278,455
|
2,001,849
|
1,649,366 |
| Financial expenses |
18,519
|
12,268
|
8,644 |
| Earnings before taxes |
86,483
|
57,521
|
58,433 |
| EBITDA |
107,586
|
71,534
|
69,607 |
| Total assets |
1,073,186
|
752,118
|
661,352 |
| Current assets |
1,059,758
|
738,074
|
647,215 |
| Current liabilities |
388,168
|
345,598
|
306,606 |
| Equity capital |
155,590
|
133,596
|
94,687 |
| - share capital |
5,156
|
5,065
|
4,730 |
| Employees (average) |
142
|
189
|
206 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
14.5%
|
17.8%
|
14.3% |
| Turnover per employee |
16,045
|
10,592
|
8,007 |
| Profit as a percentage of turnover |
3.8%
|
2.9%
|
3.5% |
| Return on assets (ROA) |
9.8%
|
9.3%
|
10.1% |
| Current ratio |
273.0%
|
213.6%
|
211.1% |
| Return on equity (ROE) |
55.6%
|
43.1%
|
61.7% |
| Change turnover |
240,511
|
235,449
|
91,597 |
| Change turnover % |
12%
|
13%
|
6% |
| Chg. No. of employees |
-47
|
-17
|
-10 |
| Chg. No. of employees % |
-25%
|
-8%
|
-5% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.